The global brucellosis vaccines market size is predicted to grow around USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.
Key Points
- The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
- North America has dominated the market with revenue share of 43% in 2023.
- By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
- By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
- By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
- By distribution channel, the public segment had the largest market share in 2023.
Brucellosis is a zoonotic infection caused by the bacteria of the genus Brucella, affecting both animals and humans. The disease is primarily transmitted from animals to humans through consumption of contaminated animal products such as milk and meat or through direct contact with infected animals. Brucellosis vaccines play a key role in controlling the spread of the disease in livestock populations, thereby reducing the risk of transmission to humans. The global brucellosis vaccines market is expected to experience steady growth in the coming years due to increasing awareness and the implementation of vaccination programs to manage brucellosis outbreaks.
Get a Sample: https://www.precedenceresearch.com/sample/4113
Growth Factors:
The growth of the brucellosis vaccines market is primarily driven by the rising prevalence of the disease in animals, particularly in developing regions where the lack of effective control measures contributes to higher infection rates. Additionally, increased government initiatives to control zoonotic diseases and the adoption of vaccination programs in livestock are expected to boost market growth. Advances in vaccine technology, such as the development of more effective and safe vaccines, are also contributing to market expansion.
Region Insights:
The global brucellosis vaccines market is segmented into different regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In North America and Europe, strict regulations and strong veterinary infrastructure support effective vaccination programs, driving market growth. In the Asia-Pacific region, countries like India and China are witnessing significant growth due to large livestock populations and increasing investment in animal health. Latin America and the Middle East & Africa face challenges with high disease prevalence but are also seeing growth opportunities as governments work to improve disease control measures.
Brucellosis Vaccines Market Scope
| Report Coverage | Details |
| Global Market Size in 2023 | USD 242.70 Million |
| Global Market Size in 2024 | USD 254.46 Million |
| Global Market Size by 2033 | USD 389.50 Million |
| Growth Rate from 2024 to 2033 | CAGR of 4.84% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Vaccine, By Application, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Brucellosis Vaccines Market Dynamics
Drivers:
Key drivers for the brucellosis vaccines market include the need to prevent and control brucellosis in livestock, increasing awareness of zoonotic diseases, and the economic impact of the disease on agriculture. Additionally, growing investments in veterinary healthcare and government policies supporting disease control measures contribute to market growth.
Opportunities:
There are numerous opportunities in the brucellosis vaccines market, such as the development of more effective and safer vaccines, including those based on new technologies like mRNA vaccines. There is also potential for expanding market reach into emerging markets with large livestock populations and high demand for effective vaccines.
Challenges:
Challenges in the brucellosis vaccines market include the complexity of vaccine development, potential side effects, and the need for proper distribution and storage of vaccines. Additionally, vaccine hesitancy and lack of awareness in some regions can hinder market growth. Addressing these challenges requires ongoing research and collaboration between governments, research institutions, and the private sector.
Read Also: Dental Caries Treatment Market Size to Rise USD 11.60 Bn by 2033
Brucellosis Vaccines Market Recent Developments
- In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
- In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
- In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
- In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.
Brucellosis Vaccines Market Companies
- Merck & Co.
- CZ Vaccines
- Colorado Serum Company
- Indian Immunologicals
- Hester Biosciences
- Veterinary Technologies Corporation
- Laboratorios Tornel
- Five Animal Health
- VETAL Animal Health Products Inc.
Segments Covered in the Report
By Type
- Rbs1 Vaccine
- S19 Vaccine
- Others
By Vaccine
- DNA Vaccine
- Subunit Vaccine
- Vector Vaccine
- Recombinant Vaccine
By Application
- Cattle
- Sheep & Goat
- Others
By Distribution Channel
- Veterinary Hospitals & Clinics
- Retail Channels
- Public
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
